Effect of a Proprietary Dietary Supplement on Fecal Volatile Organic Compounds

February 21, 2017 updated by: Pharmanex

Effect of a Proprietary Dietary Supplement on Fecal Volatile Organic Compounds - a Randomized, Placebo-controlled, Double-blind, Cross-over Study

The purpose of the study is to determine the effects of both an anthocyanin-rich polyphenol blend and an anthocyanin-rich polyphenol blend combined with a prebiotic blend on fecal microbiota metabolism (assessed by gas chromatograph - mass spectrometry (GC-MS) headspace analysis) and fecal microbiota composition (assessed by next generation sequencing).

Study Overview

Study Type

Interventional

Enrollment (Actual)

27

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Utah
      • Logan, Utah, United States, 84322
        • Utah State University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female of any race or ethnicity between 18 to 70 years of age, inclusive;
  • Body mass index (BMI) between 20 - 32 inclusive;
  • Non-smoking status;
  • Willing to consume assigned dietary supplements for a total of 6 weeks;
  • Have access to email and a digital camera or camera phone.

Exclusion Criteria:

  • Age <18 or >70 years;
  • BMI <20 or >32;
  • Uncontrolled hypertension defined as diastolic blood pressure ≥95 mm Hg or systolic blood pressure ≥160 mm Hg;
  • Self-reported presence of atherosclerotic disease and/or cardiopulmonary disease;
  • Renal, hepatic, endocrine, gastrointestinal or other systemic disease;
  • For women, pregnancy, breast feeding or postpartum less than 6 months;
  • Current participation in another research study;
  • Allergy to the components in the dietary supplement (inulin, fructooligosaccharide, blueberries, black currant, rice);
  • History of drug or alcohol abuse;
  • Use of antibiotics within the last 6 months;
  • Use of prebiotics or flavonoid-containing dietary supplements within the last 30 days;
  • Multiple food allergies or significant food preferences or restrictions that would interfere with diet adherence;
  • Chronic use of over-the-counter medication which would interfere with study endpoints including NSAIDS, laxatives and antacids;
  • Participating in or planning to begin a weight loss diet during the study period;
  • Lifestyle or schedule incompatible with the study protocol;
  • Other medical, psychiatric, or behavioral conditions that in the view of the principal investigator may present a safety hazard to the participant or interfere with study participation or the ability to follow the intervention protocol;
  • Use of tobacco products.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: OTHER
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Placebo,Flavonoids,Flavonoids+Prebiotics
Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
A combination of maltodextrins and red and blue food colors.
A combination of blueberry extract, black current extract, and black rice extract.
A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.
Experimental: Placebo,Flavonoids+Prebiotics,Flavonoids
Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
A combination of maltodextrins and red and blue food colors.
A combination of blueberry extract, black current extract, and black rice extract.
A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.
Experimental: Flavonoids,Placebo,Flavonoids+Prebiotics
Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
A combination of maltodextrins and red and blue food colors.
A combination of blueberry extract, black current extract, and black rice extract.
A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.
Experimental: Flavonoids,Flavonoids+Prebiotics,Placebo
Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
A combination of maltodextrins and red and blue food colors.
A combination of blueberry extract, black current extract, and black rice extract.
A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.
Experimental: Flavonoids+Prebiotics,Placebo,Flavonoids
Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
A combination of maltodextrins and red and blue food colors.
A combination of blueberry extract, black current extract, and black rice extract.
A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.
Experimental: Flavonoids+Prebiotics,Flavonoids,Placebo
Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
A combination of maltodextrins and red and blue food colors.
A combination of blueberry extract, black current extract, and black rice extract.
A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline in fecal volatile methyl sulfides at day 21, day 63, day 105
Time Frame: baseline, day 21, day 63, day 105
assessed by gas chromatograph - mass spectrometry (GC-MS) headspace analysis
baseline, day 21, day 63, day 105

Secondary Outcome Measures

Outcome Measure
Time Frame
Change from baseline in all fecal VOCs at day 21, day 63, day 105
Time Frame: baseline, day 21, day 63, day 105
baseline, day 21, day 63, day 105
Change from baseline fecal short chain fatty acids at day 21, day 63, day 105
Time Frame: baseline, day 21, day 63, day 105
baseline, day 21, day 63, day 105
Change from baseline fecal microbiota composition at day 21, day 63, day 105
Time Frame: baseline, day 21, day 63, day 105
baseline, day 21, day 63, day 105

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2016

Primary Completion (Actual)

February 1, 2017

Study Completion (Actual)

February 1, 2017

Study Registration Dates

First Submitted

August 15, 2016

First Submitted That Met QC Criteria

August 15, 2016

First Posted (Estimate)

August 18, 2016

Study Record Updates

Last Update Posted (Actual)

February 23, 2017

Last Update Submitted That Met QC Criteria

February 21, 2017

Last Verified

February 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • 16-PHX-0003

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Placebo

3
Subscribe